All US states have laws addressing decision making for individuals who cannot make their own medical decisions, including provisions for advance directives and processes authorizing relatives or interested persons to direct care as surrogate decision makers, 1 although variation among state laws is increasingly recognized.
2,3 However, the prevalence and content of state statutes and official advance directive documents addressing treatment decisions for decisionally incapacitated pregnant women is unknown.
Methods | Using the Nexis Uni and Fastcase databases, 3 authors (E.S.D., B.P.S., and C.K.D.) conducted parallel searches to identify statutes governing treatment decisions for incapacitated pregnant women effective in February 2019 from the 50 states and the District of Columbia. We compiled official state advance directive documents from each state's legislature, administrative agency (eg, department of health), and bar association. We performed serial analyses to identify (1) presence or absence of language referencing pregnancy; (2) whether pregnancy affected advance directives, surrogate decision making on the woman's behalf, or both; (3) whether likelihood of fetal survival was a criterion for decisions about withholding or withdrawing life-sustaining therapies; and (4) whether pregnancy restrictions codified in a given state's statutes were noted in its official advance directive. Disagreements were resolved by discussion among all authors.
Results | Thirty-eight states identified pregnancy as a condition that influences either an incapacitated woman's advance directive or surrogate decision making (Figure) . (Table) . Of the 28 states with statutory pregnancy restrictions, 68% of official advance directive forms did not disclose their pregnancy restrictions.
Of the 30 states with a pregnancy restriction, 25 specifically invalidated a woman's advance directive during pregnancy (Table) . Nineteen states prohibited a surrogate decision maker from withdrawing life-sustaining therapies from a pregnant woman.
Eighteen of the 30 states with restrictions imposed these limits only when, in the opinion of the treating physician, the fetus could survive with continued application of lifesustaining therapies to the woman. The remaining 12 states required that life-sustaining therapies continue to be provided to a decisionally incapacitated pregnant woman until her fetus could be safely delivered.
Three states (Alaska, Georgia, and Oklahoma) required physicians to test for pregnancy before withholding or withdrawing life-sustaining therapies from female patients of childbearing age. Five states (Kentucky, New Hampshire, North Dakota, Pennsylvania, and South Dakota) specified that life-sustaining therapies may be discontinued if they cause the woman undue pain that cannot be alleviated by medication. Pennsylvania assumed the financial burden of providing ongoing life-sustaining therapies to a pregnant woman who lacks decisional capacity and has an end-stage medical condition or is permanently unconscious.
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Discussion | Ethics and health law in the United States prioritize patient self-determination and freedom from unwanted medical treatment. When decision making capacity has been lost, these tenets can still be upheld by using advance directives or by respecting the choices of surrogate decision makers.
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However, this analysis suggests that a majority of US states restrict the health care options available to decisionally incapacitated women during pregnancy and do not disclose these restrictions in advance directive forms. Although states have an obligation to be transparent about pregnancy restrictions, the heterogeneity among state laws and the justification for these restrictions warrant further ethical and legal scrutiny. Neither the frequency with which these statutes are encountered nor their effect on clinical practice is known. It is unclear whether the current legal framework achieves an ethical balance between the state's interest in preserving fetal life and the interests incapacitated women may have in forgoing life-sustaining treatments. 
